A recent report published by Infinium Global Research on the blood screening market provides an in-depth analysis of segments and sub-segments in the global as well as regional blood screening market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional blood screening market over the short term as well as long term. The report is a comprehensive presentation of trends, forecasts, and dollar values of the global blood screening market. According to the report, the global blood screening market is projected to grow at a CAGR of over 11% over the forecast period of 2022-2028, growing from nearly USD 2.5 billion in 2022 to about USD 4.7 billion in 2028.
A blood screening is a procedure used in medicine to check for a specific disease or condition by scanning the patient's blood. Depending on the medical operation being performed, these steps change. The main element driving the need for blood screening and, consequently, the market's rapid expansion is an increase in the frequency of blood donation and transfusion. The main drivers of market expansion include things like rising blood donations and screenings connected to blood transfusions, rising infectious disease prevalence; an aging population; and more knowledge of disorders related to transfusions. The report on the worldwide blood screening market offers a comprehensive analysis of the industry. The research provides a thorough analysis of important market segments, trends, drivers, obstacles, the competitive environment, and other factors that are playing a substantial role in the market.
The availability and need for complex surgical treatments, such as cardiovascular and transplant surgery, trauma care, and therapy for cancer and blood illnesses, are increasing the demand for donated blood. Around the world, 235 million major surgeries are performed year on average, of which 63 million are performed due to trauma, over 31 million due to cancer, and 10 million due to pregnancy-related complications. In order to prepare for trauma, congenital maternal blood abnormalities in children, acute anemia, and other complications during labor and delivery, blood transfusions are typically advised. Digital immunoassays, which use a grid of femtoliter-sized wells in ELISA, are a one-stop shop for single-molecule detection without the need for washing procedures. In this test, a biomarker molecule that has been conjugated, amplified by an enzyme process, and detected by fluorescence is seeded in a well along with an antibody-coated magnetic microparticle. These assays have received a lot of attention since there is an urgent need for serological COVID-19 antibody tests that are inexpensive, rapid, simple, highly sensitive, quantitative, and minimally invasive. Therefore, a rapid, incredibly sensitive immunoassay that only requires a droplet of serum in one step has been developed to measure human serological IgG against SARS-CoV-2.
Due to the region's high frequency of novel infections, rising blood donation rates, and the existence of top-notch infrastructure in hospitals and clinical laboratories, North America now has a dominant position in the market. North America is also home to market players such as Abbott Laboratories, Bio-Rad Laboratories, Inc., and Thermo Fisher Scientific Inc. Thus, this has also been an influential factor in the growth of the market in North America. Due to the region's expanding affordability of healthcare, higher awareness of blood donations, and increased focus of key industry players on its emerging and developing nations, Asia-Pacific is predicted to see a swift and profitable development rate during the projection period.
The report on the global blood screening market covers segments such as product type, technology, and end-user. On the basis of product type, the sub-markets include reagents & kits, instruments, and software & services. On the basis of technology, the sub-markets include nucleic acid amplification, ELISA, rapid tests, NGS, and western bot assay. On the basis of end-user, the sub-markets include blood banks, and hospitals.
The report provides profiles of the companies in the market such as Bio-Rad Laboratories, Inc., Grifols, S.A., F. Hoffmann-La Roche, Ortho Clinical Diagnostics, BD DiaSorin S.p.A., Thermo Fisher Scientific Inc., Abbott Laboratories, QUOTIENT Technology, Immucor., and Hologic Inc.
The report provides deep insights into demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the blood screening market. Moreover, the study highlights current market trends and provides forecasts from 2022-2028. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings insight into the market share of the leading players.
Please Choose One of them.